Vault-13

Lynx1 Capital Management LP

DORADO, PR · CIK 1910456 · 13F filing filed 2022-08-15

SEC-registered investment adviser since 2023 · limited partnership

As an employer

$117.4m reported value +9.0% vs Q1 2022
12positions
99.1%in top 10
1 new 9 added 1 reduced 3 sold out vs Q1 2022

This report includes the holdings of 1 other manager that shares the investment decisions:

Shares in two reports are counted once in each security's totals.

Holdings, Q2 2022

The small lines show how much was held over the last 4 quarters (adjusted for stock splits).

#SecurityTickerShares Value% of portfolioChangeShares change
1 BELLUS HEALTH INC NEW COM NEW BLU BLU 2,831,588 $26.2m22.29% 22.29% ReducedShares held: Q3 2021 —, Q4 2021 2.0m, Q1 2022 2.9m, Q2 2022 2.8m -20.0k -20,000 -0.7%
2 MERUS N V COM MRUS MRUS 1,001,217 $22.7m19.31% 19.31% AddedShares held: Q3 2021 —, Q4 2021 783.4k, Q1 2022 893.5k, Q2 2022 1.0m +107.7k +107,690 12.1%
3 KINNATE BIOPHARMA INC COM KNTE KNTE 1,674,677 $21.1m17.99% 17.99% AddedShares held: Q3 2021 —, Q4 2021 0, Q1 2022 692.5k, Q2 2022 1.7m +982.2k +982,169 141.8%
4 ALPINE IMMUNE SCIENCES INC COM NVLS NVLS 1,926,869 $16.4m13.97% 13.97% AddedShares held: Q3 2021 —, Q4 2021 1.3m, Q1 2022 1.5m, Q2 2022 1.9m +442.2k +442,176 29.8%
5 CYMABAY THERAPEUTICS INC COM CBAY CBAY 2,589,679 $7.6m6.51% 6.51% AddedShares held: Q3 2021 —, Q4 2021 1.2m, Q1 2022 1.4m, Q2 2022 2.6m +1.2m +1,201,174 86.5%
6 PARDES BIOSCIENCES INC COM COM 2,180,560 $6.7m5.70% 5.70% AddedShares held: Q3 2021 —, Q4 2021 401.6k, Q1 2022 1.6m, Q2 2022 2.2m +537.7k +537,726 32.7%
7 PIERIS PHARMACEUTICALS INC COM COM 3,223,334 $6.0m5.14% 5.14% AddedShares held: Q3 2021 —, Q4 2021 383.3k, Q1 2022 1.1m, Q2 2022 3.2m +2.1m +2,087,015 183.7%
8 IMMUNIC INC COM COM 1,104,241 $3.8m3.26% 3.26% NewShares held: Q3 2021 —, Q4 2021 0, Q1 2022 0, Q2 2022 1.1m
9 AEROVATE THERAPEUTICS INC COM COM 191,565 $3.0m2.55% 2.55% AddedShares held: Q3 2021 —, Q4 2021 0, Q1 2022 67.0k, Q2 2022 191.6k +124.6k +124,588 186.0%
10 THESEUS PHARMACEUTICALS INC COM COM 504,862 $2.8m2.38% 2.38% AddedShares held: Q3 2021 —, Q4 2021 409.4k, Q1 2022 356.8k, Q2 2022 504.9k +148.0k +148,035 41.5%
11 PASSAGE BIO INC COM COM 421,410 $995.0k0.85% 0.85% AddedShares held: Q3 2021 —, Q4 2021 0, Q1 2022 105.5k, Q2 2022 421.4k +315.9k +315,906 299.4%
12 OTONOMY INC COM OTIC OTIC 30,000 $62.0k0.05% 0.05% UnchangedShares held: Q3 2021 —, Q4 2021 30.0k, Q1 2022 30.0k, Q2 2022 30.0k

Sold out since Q1 2022

SecurityTickerShares held beforeValue then
TRAVERE THERAPEUTICS INC TVTX TVTX 411,680 $10.6m411.7k shares
IMMUNOGEN INC IMGN IMGN 1,543,259 $7.3m1.5m shares
ELEVATION ONCOLOGY INC 10,000 $25.0k10.0k shares

Stakes above 5%

Companies where this manager has reported owning more than 5% of a class of shares, on Schedule 13D (may seek influence) or 13G (passive): its latest filing for each, from 19 Dec 2024 on.

CompanyTickerStakeChange ScheduleLast filed
PASSAGE BIO INC 13D · filed 2026-07-02 21.0% +1.4 pts 13D 2026-07-02
GH RESEARCH PLC GHRS · 13G · filed 2026-08-14 GHRS 19.3%≈ $354.0m +1.9 pts 13G 2026-08-14
NEUPHORIA THERAPEUTICS INC NEUP · 13D · filed 2025-12-29 NEUP 16.3%≈ $3.8m no change 13D 2025-12-29
TSCAN THERAPEUTICS INC TCRX · 13G · filed 2026-08-14 TCRX 13.1%≈ $3.4m -1.9 pts 13G 2026-08-14
KORRO BIO INC KRRO · 13G · filed 2026-04-02 KRRO 10.7%≈ $20.3m +2.9 pts 13G 2026-04-02
C4 THERAPEUTICS INC CCCC · 13G · filed 2026-08-14 CCCC 10.0%≈ $63.1m +2.7 pts 13G 2026-08-14
CULLINAN THERAPEUTICS INC CGEM · 13G · filed 2025-11-14 CGEM 9.8%≈ $105.0m -4.7 pts 13G 2025-11-14
STOKE THERAPEUTICS INC STOK · 13G · filed 2026-08-14 STOK 6.5%≈ $132.1m -1.6 pts 13G 2026-08-14
IBIO INC IBIO · 13G · filed 2026-08-14 IBIO 5.4%≈ $4.9m +5.4 pts 13G 2026-08-14
PRECISION BIOSCIENCES INC DTIL · 13G · filed 2026-07-20 DTIL 5.4%≈ $10.9m +1.3 pts 13G 2026-07-20
AGIOS PHARMACEUTICALS INC AGIO · 13G · filed 2026-05-06 AGIO 5.1%≈ $111.8m new 13G 2026-05-06